BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abed Y, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infect Dis 2017;4:ofx105. [PMID: 28852674 DOI: 10.1093/ofid/ofx105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Lim JJ, Dar S, Venter D, Horcajada JP, Kulkarni P, Nguyen A, Mcbride JM, Deng R, Galanter J, Chu T, Newton EM, Tavel JA, Peck MC. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open Forum Infectious Diseases 2022;9:ofab630. [DOI: 10.1093/ofid/ofab630] [Reference Citation Analysis]
2 Shin WJ, Seong BL. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. Expert Opin Drug Discov 2019;14:153-68. [PMID: 30585088 DOI: 10.1080/17460441.2019.1560261] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zyryanov SK, Butranova OI, Gaidai DS, Kryshen KL. [Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities]. Ter Arkh 2021;93:114-24. [PMID: 33720636 DOI: 10.26442/00403660.2021.01.200551] [Reference Citation Analysis]
4 Wacquiez A, Coste F, Kut E, Gaudon V, Trapp S, Castaing B, Marc D. Structure and Sequence Determinants Governing the Interactions of RNAs with Influenza A Virus Non-Structural Protein NS1. Viruses 2020;12:E947. [PMID: 32867106 DOI: 10.3390/v12090947] [Reference Citation Analysis]
5 Li J, Yang Z, Mao LF, Chen RH, Yu XF, Yang XH, Zhang GZ, Wang HQ, Chen SC, Zhao G. Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance. Mol Cell Probes 2021;60:101771. [PMID: 34560257 DOI: 10.1016/j.mcp.2021.101771] [Reference Citation Analysis]
6 Tu V, Abed Y, Fage C, Baz M, Boivin G. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. Antiviral Res 2018;154:110-5. [PMID: 29674164 DOI: 10.1016/j.antiviral.2018.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Abed Y, Fage C, Lagüe P, Carbonneau J, Papenburg J, Vinh DC, Boivin G. Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. Emerg Infect Dis 2019;25:838-40. [PMID: 30882323 DOI: 10.3201/eid2504.181554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Abi Hussein H, Geneix C, Cauvin C, Marc D, Flatters D, Camproux AC. Molecular Dynamics Simulations of Influenza A Virus NS1 Reveal a Remarkably Stable RNA-Binding Domain Harboring Promising Druggable Pockets. Viruses 2020;12:E537. [PMID: 32422922 DOI: 10.3390/v12050537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 2020;39:1201-8. [PMID: 32056049 DOI: 10.1007/s10096-020-03840-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 21.5] [Reference Citation Analysis]
10 Warfield KL, Schaaf KR, DeWald LE, Spurgers KB, Wang W, Stavale E, Mendenhall M, Shilts MH, Stockwell TB, Barnard DL, Ramstedt U, Das SR. Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B. Sci Rep 2019;9:7484. [PMID: 31097731 DOI: 10.1038/s41598-019-43030-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Chen L, Han X, Li YL, Zhang C, Xing X. The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study. BMC Infect Dis 2020;20:628. [PMID: 32842994 DOI: 10.1186/s12879-020-05322-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. The Journal of Infectious Diseases 2019. [DOI: 10.1093/infdis/jiz244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
13 McKimm-Breschkin JL, Barrett S, McKenzie-Kludas C, McAuley J, Streltsov VA, Withers SG. Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant. Antiviral Res 2019;169:104542. [PMID: 31233807 DOI: 10.1016/j.antiviral.2019.104542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Thakur V, Ratho RK, Panda JJ. Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19. Virusdisease 2021;:1-6. [PMID: 33748347 DOI: 10.1007/s13337-021-00679-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lloren KKS, Kwon JJ, Choi WS, Jeong JH, Ahn SJ, Choi YK, Baek YH, Song MS. In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection. J Virol 2019;93:e01825-18. [PMID: 30602610 DOI: 10.1128/JVI.01825-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Slain D. Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza. Ann Pharmacother 2021;55:760-71. [DOI: 10.1177/1060028020963616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 de Freitas CS, Rocha MEN, Sacramento CQ, Marttorelli A, Ferreira AC, Rocha N, de Oliveira AC, de Oliveira Gomes AM, Dos Santos PS, da Silva EO, da Costa JP, de Lima Moreira D, Bozza PT, Silva JL, Barroso SPC, Souza TML. Agathisflavone, a Biflavonoid from Anacardium occidentale L., Inhibits Influenza Virus Neuraminidase. Curr Top Med Chem 2020;20:111-20. [PMID: 31854280 DOI: 10.2174/1568026620666191219150738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Langeder J, Grienke U, Chen Y, Kirchmair J, Schmidtke M, Rollinger JM. Natural products against acute respiratory infections: Strategies and lessons learned. J Ethnopharmacol 2020;248:112298. [PMID: 31610260 DOI: 10.1016/j.jep.2019.112298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Matheeussen V, Loens K, Kuijstermans M, Jacobs K, Coenen S, van der Velden AW, Bongard E, Butler CC, Verheij TJ, Goossens H, Ieven M. Diagnostic performance of the Idylla™ respiratory panel for molecular detection of influenza A/B in patients presenting to primary care with influenza-like illness during 3 consecutive influenza seasons. J Clin Virol 2021;144:104998. [PMID: 34653942 DOI: 10.1016/j.jcv.2021.104998] [Reference Citation Analysis]
20 Atto B, Eapen MS, Sharma P, Frey U, Ammit AJ, Markos J, Chia C, Larby J, Haug G, Weber HC, Mabeza G, Tristram S, Myers S, Geraghty DP, Flanagan KL, Hansbro PM, Sohal SS. New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci (Lond) 2019;133:1663-703. [PMID: 31346069 DOI: 10.1042/CS20181009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
21 Checkmahomed L, Padey B, Pizzorno A, Terrier O, Rosa-Calatrava M, Abed Y, Baz M, Boivin G. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses 2020;12:E1139. [PMID: 33049959 DOI: 10.3390/v12101139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Silva T, S Salomon P, Hamerski L, Walter J, B Menezes R, Siqueira JE, Santos A, Santos JAM, Ferme N, Guimarães T, O Fistarol G, I Hargreaves P, Thompson C, Thompson F, Souza TM, Siqueira M, Miranda M. Inhibitory effect of microalgae and cyanobacteria extracts on influenza virus replication and neuraminidase activity. PeerJ 2018;6:e5716. [PMID: 30386690 DOI: 10.7717/peerj.5716] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 Brodskaia AV, Timin AS, Gorshkov AN, Muslimov AR, Bondarenko AB, Tarakanchikova YV, Zabrodskaya YA, Baranovskaya IL, Il'inskaja EV, Sakhenberg EI, Sukhorukov GB, Vasin AV. Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. Antiviral Res 2018;158:147-60. [PMID: 30092251 DOI: 10.1016/j.antiviral.2018.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis 2018;31:520-6. [PMID: 30299356 DOI: 10.1097/QCO.0000000000000498] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 13.7] [Reference Citation Analysis]
25 Nakazawa M, Hara K, Komeda T, Ogura E. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients. J Infect Chemother 2020;26:729-35. [PMID: 32409018 DOI: 10.1016/j.jiac.2020.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]